MIMEDX GROUP INC (MDXG) Fundamental Analysis & Valuation
NASDAQ:MDXG • US6024961012
Current stock price
3.2 USD
-0.05 (-1.54%)
At close:
3.2 USD
0 (0%)
After Hours:
This MDXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDXG Profitability Analysis
1.1 Basic Checks
- In the past year MDXG was profitable.
- MDXG had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
- In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 14.18%, MDXG belongs to the top of the industry, outperforming 94.57% of the companies in the same industry.
- The Return On Equity of MDXG (18.94%) is better than 95.16% of its industry peers.
- The Return On Invested Capital of MDXG (16.82%) is better than 96.32% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MDXG is significantly below the industry average of 27.75%.
- The last Return On Invested Capital (16.82%) for MDXG is above the 3 year average (16.63%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| ROIC | 16.82% |
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
1.3 Margins
- MDXG's Profit Margin of 11.60% is amongst the best of the industry. MDXG outperforms 91.47% of its industry peers.
- The Operating Margin of MDXG (15.26%) is better than 92.05% of its industry peers.
- MDXG's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 82.56%, MDXG belongs to the best of the industry, outperforming 85.27% of the companies in the same industry.
- In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.26% | ||
| PM (TTM) | 11.6% | ||
| GM | 82.56% |
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
2. MDXG Health Analysis
2.1 Basic Checks
- MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for MDXG has been increased compared to 1 year ago.
- The number of shares outstanding for MDXG has been increased compared to 5 years ago.
- Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
- MDXG has an Altman-Z score of 5.77. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
- MDXG has a Altman-Z score of 5.77. This is in the better half of the industry: MDXG outperforms 73.64% of its industry peers.
- MDXG has a debt to FCF ratio of 0.25. This is a very positive value and a sign of high solvency as it would only need 0.25 years to pay back of all of its debts.
- MDXG's Debt to FCF ratio of 0.25 is amongst the best of the industry. MDXG outperforms 95.74% of its industry peers.
- A Debt/Equity ratio of 0.06 indicates that MDXG is not too dependend on debt financing.
- MDXG's Debt to Equity ratio of 0.06 is in line compared to the rest of the industry. MDXG outperforms 40.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.25 | ||
| Altman-Z | 5.77 |
ROIC/WACC1.77
WACC9.5%
2.3 Liquidity
- MDXG has a Current Ratio of 4.32. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of MDXG (4.32) is comparable to the rest of the industry.
- MDXG has a Quick Ratio of 3.92. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- MDXG has a Quick ratio (3.92) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.32 | ||
| Quick Ratio | 3.92 |
3. MDXG Growth Analysis
3.1 Past
- MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.38%, which is quite impressive.
- Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 19.99% in the last year.
- The Revenue has been growing by 11.02% on average over the past years. This is quite good.
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
3.2 Future
- MDXG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.82% yearly.
- Based on estimates for the next years, MDXG will show a small growth in Revenue. The Revenue will grow by 4.92% on average per year.
EPS Next Y-72.63%
EPS Next 2Y-24.36%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. MDXG Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 7.80 indicates a rather cheap valuation of MDXG.
- Based on the Price/Earnings ratio, MDXG is valued cheaper than 97.48% of the companies in the same industry.
- MDXG is valuated cheaply when we compare the Price/Earnings ratio to 27.71, which is the current average of the S&P500 Index.
- MDXG is valuated quite expensively with a Price/Forward Earnings ratio of 28.52.
- Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 93.22% of the companies in the same industry.
- MDXG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 38.09.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.8 | ||
| Fwd PE | 28.52 |
4.2 Price Multiples
- MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 98.06% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 99.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.52 | ||
| EV/EBITDA | 4.25 |
4.3 Compensation for Growth
- The decent profitability rating of MDXG may justify a higher PE ratio.
- A cheap valuation may be justified as MDXG's earnings are expected to decrease with -7.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.36%
EPS Next 3Y-7.32%
5. MDXG Dividend Analysis
5.1 Amount
- MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDXG Fundamentals: All Metrics, Ratios and Statistics
3.2
-0.05 (-1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)05-05 2026-05-05
Inst Owners73.24%
Inst Owner Change0.66%
Ins Owners2.34%
Ins Owner Change1.43%
Market Cap475.42M
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Analysts81.67
Price Target9.86 (208.12%)
Short Float %5.29%
Short Ratio7.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.4%
Min EPS beat(2)16.71%
Max EPS beat(2)110.08%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)6.95%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)37.48%
EPS beat(12)11
Avg EPS beat(12)67.57%
EPS beat(16)12
Avg EPS beat(16)46.59%
Revenue beat(2)2
Avg Revenue beat(2)13.43%
Min Revenue beat(2)8.43%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)8.47%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)3.74%
PT rev (1m)0%
PT rev (3m)-20.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-180%
EPS NY rev (1m)-2.94%
EPS NY rev (3m)-55.1%
Revenue NQ rev (1m)-4.81%
Revenue NQ rev (3m)-30.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.8 | ||
| Fwd PE | 28.52 | ||
| P/S | 1.14 | ||
| P/FCF | 6.52 | ||
| P/OCF | 6.42 | ||
| P/B | 1.85 | ||
| P/tB | 2.13 | ||
| EV/EBITDA | 4.25 |
EPS(TTM)0.41
EY12.81%
EPS(NY)0.11
Fwd EY3.51%
FCF(TTM)0.49
FCFY15.35%
OCF(TTM)0.5
OCFY15.57%
SpS2.82
BVpS1.73
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.99119 (24.72%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| ROCE | 22.95% | ||
| ROIC | 16.82% | ||
| ROICexc | 41.72% | ||
| ROICexgc | 59.54% | ||
| OM | 15.26% | ||
| PM (TTM) | 11.6% | ||
| GM | 82.56% | ||
| FCFM | 17.43% |
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
ROICexc(3y)34.07%
ROICexc(5y)N/A
ROICexgc(3y)46.74%
ROICexgc(5y)N/A
ROCE(3y)22.68%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.46%
ROICexc growth 3YN/A
ROICexc growth 5Y12.11%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.25 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 6.94% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 51.27 | ||
| Cash Conversion | 93.95% | ||
| Profit Quality | 150.21% | ||
| Current Ratio | 4.32 | ||
| Quick Ratio | 3.92 | ||
| Altman-Z | 5.77 |
F-Score5
WACC9.5%
ROIC/WACC1.77
Cap/Depr(3y)32.56%
Cap/Depr(5y)46.17%
Cap/Sales(3y)0.47%
Cap/Sales(5y)0.75%
Profit Quality(3y)118.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-72.63%
EPS Next 2Y-24.36%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
EBIT growth 1Y26.23%
EBIT growth 3YN/A
EBIT growth 5Y33.44%
EBIT Next Year-18.28%
EBIT Next 3Y13.89%
EBIT Next 5Y12.12%
FCF growth 1Y13.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
How profitable is MIMEDX GROUP INC (MDXG) stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 7 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 7.8 and the Price/Book (PB) ratio is 1.85.
Can you provide the expected EPS growth for MDXG stock?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -72.63% in the next year.